ACT Signature Webinar series provides accessible education to members of the toxicology community worldwide. The Signature Webinars are held on a quarterly basis and are free to both ACT members and nonmembers for live and on-demand viewing.
These educational webinars cover current topics in toxicology and are presented by experts in the field, with backgrounds in government, industry, or academia. Each Signature Webinar is approximately 90 minutes, which includes a 30-minute questions and answers session with the speaker(s) following the presentation.
After the live webinar, a recording will be available approximately one week after event. Signature Webinar recordings can be accessed from the Webinar Archives for one year. ACT members can access all past webinar recordings from the Member-Only Archives.
Upcoming Webinar
Signature Webinar
March 27, 2024, at 11:30 AM–1:00 PM Eastern
Nerve Conduction Studies to Evaluate Neuropathy in Nonclinical Safety Assessment
Hosted by the American College of Toxicology
Speakers:
Neuropathy refers to any condition involving peripheral nervous system damage and can develop as a side effect of certain classes of therapeutic compounds, from toxin exposure, or due to disease. Given the clinical significance of neuropathy, it can be critical to characterize nerve function during the nonclinical safety assessment of certain classes of compounds. In addition, recent characterization of dorsal root ganglion toxicity following AAV (adeno-associated virus) therapies stresses the need to have an in-vivo assessment of potential nerve damage on these studies. Nerve conduction studies provide an electrophysiological approach to assess nerve function. They have been shown to be a sensitive and valid index of induced neuropathies, can be conducted at multiple time points throughout the treatment period, and provide quantitative data for evaluation. In this talk, we will provide an overview of nerve conduction study theory and practice in nonclinical safety assessment as well as highlight study design considerations, positive control validation data, and case study examples.
Dates, speakers, and topics are subject to change.
Signature Webinar
May 22, 2024, at 11:30 AM–1:00 PM Eastern
Translation Between Veterinary and Human Medicine to Improve Clinical Outcomes in Drug Development
Hosted by the American College of Toxicology
Speakers:
Elizabeth Neyens
Jay Stallons
Webinar Archives
- An Overview of Nonclinical Considerations in Translating AAV Gene Therapies to the Clinic
- Assessing the Environmental Risk of Pharmaceuticals following Patient Use
- Computational Toxicology: A Useful Tool for Hazard Identification and Risk Assessment?
- Defining the INDefinable: US FDA Regulatory Applications
- Fundamental Approaches to Immunotoxicity Assessment in Preclinical Safety Studies
- History and Risk Assessment of Vaccines: A Practical Perspective from an Immunologist and a Toxicologist
- Impurities: The Good, the Bad, and the Ugly
- Juvenile Animal Studies: Regulatory and Industry Perspectives
- Nonclinical Abuse Liability Testing of Biologics
- Ototoxicity: Preparation Is Key
- Preclinical Considerations for Cell-Based Immunotherapies
- Reproduction, Development, and Pathology: Finding Common Ground
- Revisiting Certifications in General Toxicology—ABT/ERT/ATS
- Safety Assessment of Metabolites in Drug Development: Current Perspective
- Safety Testing of Metabolites
- Talking Tox When Others Don’t “Speak the Language”
- The Veterinary Pathologist’s Role in the 3Rs
- Understanding Developmental and Reproductive Toxicity Studies
- Adversity in Nonclinical Reporting: Myths, Legends, and Reality
- Approach to Development of an Inhalation Excipient for Regulatory Approval: Case Studies with HFA-152a and DSPC
- How to Peer Review/How to Get Published
- Impurities Safety Evaluation
- Influence of the Microbiota in Drug Development and Preclinical Studies
- Nonclinical Safety Assessment of Prophylactic and Therapeutic Vaccines
- Preclinical Medical Device Safety Evaluation in 2022
- Preparing for Regulatory Interactions: How Much Is Enough?
- The Complement Cascade—When Activation Mediates Toxicity
- Safety Assessment of Monoclonal Antibodies for Immunosuppressants and Anti-Inflammatory Agents
- A Regulatory and Industry Perspective on the Introduction and Application of GLP Regulations: What They Are, Why They Matter, and How They Apply to Toxicology Studies
- Adversity in Nonclinical Reporting: Myths, Legends, and Reality
- Best Practices of Communication: How to Communicate with Your CRO and/or Client
- Carcinogenicity Assessment of Biologics
- Early Toxicology Studies—From Design to Dose Selection: What You Need to Know
- Immunological Assessments of Viral Vectors Expressing Multiple Cytokine Transgenes in Nonclinical Studies
- Implications for Tox/TK When ISR Fails
- Mini-Pig Use in Safety Assessments during Drug Development
- Pathology Peer Review and the OECD Guidance on the GLP Requirements: A Review of the Review
- Preparing for Nonclinical eData Regulatory Submissions to the US FDA—“SEND” and Beyond
- Regulatory and Scientific Challenges in Biosimilar Development: Nonclinical Considerations
- Revisiting Certifications in General Toxicology—ABT/ERT/ATS
- An Overview of Nonclinical Considerations in Translating AAV Gene Therapies to the Clinic
- Animal Models of Disease for Nonclinical Safety Assessment: Pharmaceutical Industry Survey
- Applications of iPS-Cell Derived Tissues in Safety Assessment
- Approach to Development of an Inhalation Excipient for Regulatory Approval: Case Studies with HFA-152a and DSPC
- How to Peer Review/How to Get Published
- Mechanistic Approaches Using 3D Microtissues to Evaluate Preclinical and Clinical Drug-Induced Liver Injury
- Ototoxicity: Preparation Is Key
- Practical Nanotoxicology
- The Complement Cascade—When Activation Mediates Toxicity
- Understanding Your Model: Considerations for Use of Tg.rasH2 Mice in Carcinogenicity Assessmenty